决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors.
治疗后缺乏活检,尤其是在实体瘤中,限制了对嵌合抗原受体(CAR)-T 细胞体内相关特征的理解,从而阻碍了提高 CAR-T 细胞疗效策略的开发。
缺乏治疗后活检(尤其是实体瘤)限制了对嵌合抗原受体(CAR)T细胞相关体内特征的认识,从而妨碍开发提高CAR-T疗效的策略。本研究采用来自消化系统癌症临床样本的19份独立单细胞RNA测序(scRNA-seq)数据,探究肿瘤浸润T细胞(TIL)特征,以鉴定可能增强CAR-T功能的有效靶点。数据显示,NK细胞颗粒蛋白7(NKG7)在TIL中高表达,并与消化系统癌症患者对抗PD-1或抗CTLA4治疗的应答呈正相关。随后我们发现,异位表达NKG7可显著提高靶向B7H3的CAR-T细胞对B7H3阳性消化系统癌细胞(MKN45、Huh7、HuCCT-1、SW620和PANC-1细胞)的细胞毒性,并促进TNF-α和IL-2表达。此外,在靶向CD19的CAR-T模型中,过表达NKG7也提高了治疗效力。从机制上看,NKG7可在CAR-T细胞接触相应肿瘤抗原后维持其表面CAR表达并促进细胞增殖。这些结果表明,分析临床肿瘤样本的单细胞测序数据以寻找改善CAR-T功能的策略具有可行性;异位表达NKG7是提高CAR-T细胞抗肿瘤疗效的有效方法。
Lack of biopsies after treatment, especially in solid tumors, restricts the understanding of chimeric antigen receptor (CAR)-T cells -related characteristic in vivo, thus hindering the development of strategies to improve CAR-T cells efficacy. Here, we applied nineteen individual single-cell RNA sequencing (scRNA-seq) data from clinical samples of digestive cancers to explore the characteristics of tumor-infiltrating T cells (TILs) to identify effective targets which might be benefit for enhancing the function of CAR-T cells. The data showed that natural killer cell granule protein 7 (NKG7) was overexpressed in TILs and positively associated with anti-PD1 or anti-CTLA4 therapy in digestive cancers. Subsequently, we found that ectopic expression of NKG7 significantly improved the cytotoxicity of B7H3-targeting CAR-T cells to B7H3-positive digestive cancer cells (MKN45, Huh7, HuCCT-1, SW620 and PANC-1 cells), as well as promoted the TNF- and IL-2 expression. Furthermore, in a CD19-targeting CAR-T model, the therapeutic efficacy was also found increased after NKG7 overexpression. Mechanically, NKG7 preserved surface CAR expression and promoted CAR-T cell proliferation after exposing to relative tumor antigen. These results indicated that it may be feasible to explore single-cell sequencing data of clinical tumor samples to find strategies to improve CAR-T function, and that ectopic expression of NKG7 is an effective strategy to improve the therapeutic efficacy of CAR-T cells against tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。